Apnimed, Inc.

424B4 priced

Price $16.00 · 12,000,000 shares · Gross proceeds $192,000,000

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Range $14.00 to $16.00 · 10,000,000 shares

Apnimed, Inc. updates its S-1 filing with enhanced disclosures on regulatory, manufacturing, and clinical trial risks for Oxnimbi, its lead product candidate. The company emphasizes challenges in securing FDA approval, including potential restrictions on indications, labeling disputes, and post-marketing requirements. Manufacturing process changes and clinical trial delays due to enrollment difficulties, third-party dependencies, and regulatory hurdles are detailed. The filing underscores resource constraints impacting development timelines and commercialization prospects.

S-1 filed

Apnimed, Inc. outlines significant risks related to the regulatory approval process for its product candidate Oxnimbi, including potential delays or rejections by the FDA due to manufacturing changes, limited indications, or post-marketing requirements. The company emphasizes challenges in clinical trial execution, such as patient enrollment difficulties, regulatory hurdles, and reliance on third-party contractors. Manufacturing uncertainties, limited financial resources, and the inherent risks of drug development are highlighted as critical obstacles to commercialization. The filing underscores the company's focus on Oxnimbi while acknowledging the risks of diverting resources from other potential opportunities.

DRS/A amended

DRS/A amended

DRS/A amended

DRS filed